www.alborgdx.com





: Stanislaus Lawrence Lobo **Sample Date** : 23/10/2022 11:33 AM Name

: 23/10/2022 16:01 PM **Report Date**

: Nas (WN, VN) 10% - Dubai Branch Contract. **Doctor references: Dr. Marvis Enyl**

: 30-82450 Patient No.

: 3022117506

: 37133 File No.

: Al Borg Lab. Dubai **Branch** Age: 48 Year DOB 18/02/1974 : Male Sex

Deirah

Chemistry Unit

Test Result Unit Ref. Range 70 - 100 173 Glucose in Plasma (Fasting) mg/dl Normal: 70 - 100

Pre-Diabetes: 100 -125 Diabetes: ≥ 126

Comments

Lab. No.

Primary sample: Plasma

Methodology :Enzymatic reference method with hexokinase

Reviewed By:

Dr. Shailendra Rathod.MD **Laboratory Director Physician Specialist Clinical**

Pathology

License no. 10944644-001

** End Of Report **

Verified By: Shailendra Rathod.MD

Printed By: System

All Rights Reseved © National Technology

Printed Date PM 16:31 23/10/2022

Page 1 Of 1 Powered by LDM www.nt-me.com

www.alborgdx.com





Name : Stanislaus Lawrence Lobo Sample Date : 23/10/2022 11:33 AM

: Nas (WN, VN) 10% - Dubai Branch

: 3022117506 Report Date : 23/10/2022 12:54 PM

Doctor references: Dr. Marvis Enyl

Patient No. : 30-82450

File No. : 37133

Lab. No.

Contract.

Branch : Al Borg Lab. Dubai Age : 48 Year DOB 18/02/1974 Sex : Male

Deirah

Cholesterol/HDL/LDL/Triglycerides

| Test | Result | | Unit | Ref. Range |
|---|--------|---|-------|---|
| Cholesterol | 145 | | mg/dl | No risk <200 Moderate risk 200 - 240 High risk >240 |
| Comments Primary sample: Serum Methodology: Enzymatic colorimetric assay in the presence pf peroxidase. | | | | |
| Triglycerides (TG) in Serum | 138 | | mg/dL | Normal<200 |
| Comments Primary sample: Serum Methodology: Enzymatic colorimetric assay | | | | |
| HDL Cholesterol | 44 | L | mg/dL | Optimum level ≥ 60 Borderline risk: 40-59 High risk: <40 |
| Comments Primary sample: Serum Methodology: HOmogeneous Enzymatic colorimetric assay. | | | | |
| LDL Cholesterol | 73 | | mg/dl | Optimal <100 Near optimal 100-129 Borderline high 130-159 High 160-189 Very high >189 |

Comments

Sample type: Serum Methodology: Calculation

*This is non-accredited test.

All Rights Reseved © National Technology

Printed By: System Page 1 Of 2 PM :Printed Date 16:31 23/10/2022

Powered by LDM www.nt-me.com

www.alborgdx.com





Name : Stanislaus Lawrence Lobo Sample Date : 23/10/2022 11:33 AM

Lab. No. : 3022117506 Report Date : 23/10/2022 12:54 PM

Contract. : Nas (WN, VN) 10% - Dubai Branch Doctor references : Dr. Marvis Enyl

Patient No. : 30-82450

File No. : 37133

Branch : Al Borg Lab. Dubai Age : 48 Year DOB 18/02/1974 Sex : Male

Deirah

Cholesterol/HDL/LDL/Triglycerides

| lest | Result | Unit | Ref. Range |
|---------------------|--------|-------|--|
| Non-HDL Cholesterol | 101 | mg/dL | very high >220 High 190-219 Borderline high 160-189 Near Ideal 130-159 Ideal for people at risk of heart disease <130 Ideal for people at very high risk of heart disease <100 |

Comments

Patients with elevated levels of non-HDL-C and normal levels of LDL-C, often have an increased number of LDL particles, increased apo B or increased small, dense LDL particles and these are associated with an increased risk of CVD. Therefore non-HDL-C might be more valuable indicator of cardiovascular risk than LDL-C.

The treatment goal for non-HDL cholesterol in persons with high triglycerides (>199 mg/dl) is 30 mg/dl higher than their LDL cholesterol goal.

Reviewed By:

Dr. Shailendra Rathod.MD Laboratory Director Physician Specialist Clinical Pathology

License no. 10944644-001

** End Of Report **

Verified By: Shailendra Rathod.MD

Printed By: System
All Rights Reseved © National Technology

Page 2 Of 2

PM :Printed Date 16:31 23/10/2022

Powered by LDM www.nt-me.com